Kidney Cancer at a Crossroads: What New Trial Results Could Mean for Patients
Manage episode 407462017 series 3560609
Michael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 inhibitors. They also discuss adjuvant therapy and how depth of response differs between immunotherapy and TKIs, and look ahead to what the future holds.
120 episodes